Overview

  • Product nameAnti-AKT1 (phospho T308) antibodySee all AKT1 primary antibodies ...
  • Description
    Rabbit polyclonal to AKT1 (phospho T308)
  • SpecificityThe motif corresponding to the major autophosphorylation site of the human AKT1 kinase protein. This antibody does not cross react to the non-phosphorylated AKT1 or with other unrelated phosphorylated serine.
  • Tested applicationsIHC-P, ELISA, WB, IP, Dot Blotmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Chicken, Cow, Dog, Human, Xenopus laevis, Moloney Murine Leukemia Virus, Culex pipiens
  • Immunogen

    Synthetic peptide within Human AKT1 (phospho T308). The exact sequence is proprietary.
    Sequence:

    GATMKTFCG

  • Positive control
    • PDGF stimulated 3T3 whole cell lysate

Properties

Applications

Our Abpromise guarantee covers the use of ab66134 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 1 - 2 µg/ml.
ELISA Use a concentration of 0.01 - 0.1 µg/ml.
WB Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 60 kDa.
IP Use a concentration of 2 - 5 µg/ml.
Dot Blot 1/2000.

Target

  • FunctionPlays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. The activated form can suppress FoxO gene transcription and promote cell cycle progression. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly.
  • Tissue specificityExpressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.
  • Involvement in diseaseDefects in AKT1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
    Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].
    Defects in AKT1 are associated with susceptibility to ovarian cancer [MIM:604370]; also called susceptibility to familial breast-ovarian cancer type 1 (BROVCA1).
  • Sequence similaritiesBelongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.
    Contains 1 AGC-kinase C-terminal domain.
    Contains 1 PH domain.
    Contains 1 protein kinase domain.
  • DomainBinding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI(3)K) results in its targeting to the plasma membrane. The PH domain mediates interaction with TNK2 and Tyr-176 is also essential for this interaction.
    The AGC-kinase C-terminal mediates interaction with THEM4.
  • Post-translational
    modifications
    Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for full activity. Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to the anionic plasma membrane phospholipid PA. This phosphorylated form localizes to the cell membrane, where it is targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and Ser-473 leading to its activation. Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focal cortical dysplasias with Taylor-type balloon cells.
    Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination is critical for phosphorylation and activation. When ubiquitinated, it translocates to the plasma membrane, where it becomes phosphorylated. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome.
  • Cellular localizationCytoplasm. Nucleus. Cell membrane. Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • AKT 1 antibody
    • AKT antibody
    • AKT1 antibody
    • AKT1_HUMAN antibody
    • C AKT antibody
    • MGC9965 antibody
    • MGC99656 antibody
    • Oncogene AKT1 antibody
    • PKB antibody
    • PKB-ALPHA antibody
    • PRKBA antibody
    • Protein Kinase B Alpha antibody
    • Protein kinase B antibody
    • Proto-oncogene c-Akt antibody
    • RAC Alpha antibody
    • RAC antibody
    • RAC PK Alpha antibody
    • RAC Serine/Threonine Protein Kinase antibody
    • RAC-alpha serine/threonine-protein kinase antibody
    • RAC-PK-alpha antibody
    • vAKT Murine Thymoma Viral Oncogene Homolog 1 antibody
    see all

Anti-AKT1 (phospho T308) antibody images

  • All lanes : Anti-AKT1 (phospho T308) antibody (ab66134) at 1/1000 dilution

    Lane 1 : PDGF stimulated 3T3cells
    Lane 2 : PDGF stimulated 3T3 cells with Band abolished by pre-incubation with immunizing peptide.


    Predicted band size : 60 kDa
  • 1 µg of a peptide was blotted onto a nitrocellulose membrane followed by ab66134 at 1/2000 dilution. Upper Panel: Dot 1: AKT1(pT308) peptide, Dots 2,3,4: unrelated phosphopeptides. Lower Panel: Dot 1: non phosphopeptide AKT1, Dots 2,3,4: unrelated non-phosphopeptides.

References for Anti-AKT1 (phospho T308) antibody (ab66134)

This product has been referenced in:
  • Shen R  et al. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. Cancer Lett 339:135-43 (2013). WB . Read more (PubMed: 23887057) »
  • Thrush AB  et al. A single prior bout of exercise protects against palmitate-induced insulin resistance despite an increase in total ceramide content. Am J Physiol Regul Integr Comp Physiol 300:R1200-8 (2011). WB ; Rat . Read more (PubMed: 21325642) »

See all 3 Publications for this product

Product Wall

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step Dako REAL peroxidase-blocking solution as blocking agent for 60 hour(s) and 0 minute(s) · Concentration: 100% · Temperature: 25°C
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Tris-EDTA
Sample Zebrafish Tissue sections (Liver)
Specification Liver
Permeabilization No
Fixative Paraformaldehyde
Username

Abcam user community

Verified customer

Submitted Mar 04 2014

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Loading amount 20 µg
Gel Running Conditions Reduced Denaturing (10%)
Sample Culex pipiens Tissue lysate - whole (whole fly homogenates)
Specification whole fly homogenates
Treatment blood feeding with sheep blood
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C
Username

Jiawen Xu

Verified customer

Submitted Aug 05 2013

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"